INSM · Insmed Incorporated

Insmed's Q1 2026 results showcased robust commercial momentum, with total revenues surging to $306.0 million, a 230% increase from $92.8 million in Q1 2025, primarily fueled by BRINSUPRI's inaugural full quarter post its August 2025 U.S. launch, delivering $207.9 million including $207.2 million domestically. ARIKAYCE contributed $98.1 million, up 6% YoY with international growth of 23% offsetting a slight U.S. decline. Gross cost dynamics improved as BRINSUPRI's lower manufacturing costs relative to ARIKAYCE reduced cost of product revenues as a percentage of sales, despite absolute increase to $47.4 million. Operating expenses escalated with R&D up 37% to $209.5 million due to headcount, manufacturing, and clinical investments, and SG&A rising 68% to $247.3 million from BRINSUPRI commercialization. This yielded a narrower net loss of $163.6 million or $0.76 per share versus $256.6 million or $1.42 prior year, aided by a $47.0 million favorable change in contingent consideration fair value. CEO Will Lewis highlighted BRINSUPRI's exceeding expectations and ENCORE Phase 3b success meeting all culture conversion endpoints, positioning for ARIKAYCE label expansion via H2 2026 sNDA. The company reaffirmed full-year guidance of at least $1 billion BRINSUPRI and $450-470 million ARIKAYCE revenues, supported by $1.2 billion cash position. Pipeline advances include TPIP's PALM-PAH Phase 3 initiation and ongoing PALM-ILD enrollment, plus planned INDs for INS1033 and INS1203, signaling sustained R&D intensity under 20% of expenditures.